Arctic Bioscience AS
- Address
- Industrivegen 42
Sponsor Overview
Specializations
Dermatology
Arctic Bioscience AS focuses on psoriasis, with clinical research centered on mild-to-moderate plaque disease and its treatment needs in adult patients. Its activity is directed toward therapeutic options for inflammatory skin conditions.
- Psoriasis
- Inflammatory skin disease
- Dermatologic therapeutics
The sponsor’s research interest in this area is tied to evaluating oral treatment approaches for symptom control and disease management in chronic immune-mediated skin disorders.
Immunology
The sponsor’s clinical work addresses immune-mediated inflammation relevant to psoriasis, reflecting interest in therapies that modulate the underlying inflammatory response in dermatologic disease.
- Immune-mediated disease
- Inflammatory pathways
- Skin immune regulation
This area links the company’s clinical development activity with treatment strategies aimed at reducing disease burden in patients with persistent inflammatory skin involvement.
Oral Therapeutics
Arctic Bioscience AS is active in oral treatment development, with research focused on a candidate intended for systemic management of psoriasis rather than topical control. This places emphasis on convenient administration for long-term dermatologic care.
- Oral systemic therapy
- Psoriasis treatment
- Patient-friendly administration
The company’s clinical interest lies in identifying an oral option suitable for patients requiring ongoing treatment of chronic skin inflammation.
Clinical Development
With active research sites across multiple countries, the sponsor’s clinical activity is concentrated on advancing a single investigational therapy for psoriasis through multicountry patient evaluation and treatment assessment.
- Multinational clinical research
- Therapeutic evaluation
- Drug development in dermatology
This research setting supports the company’s interest in building evidence for a targeted psoriasis therapy within the dermatology and immunology fields.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of HRO350 in subjects with mild-to-moderate psoriasis (the ‘HeROPA’ study) |  Finland Germany Norway Poland | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 49 sites across their trial portfolio.
Therapeutic Focus
- 1.Skin and Connective Tissue Diseases1 trial247 other sponsors
Partnered Research Centres
49 centres- Address
- Langenbeckstrasse 1, Oberstadt, 55131 Mainz
- Address
- Ul. Henryka Sienkiewicza 23, 30-033 Krakow
- Address
- Itainen Pitkakatu 4b, 20520 Turku
- Address
- Energiakatu 4, 00180 Helsinki
- Address
- Charlottenstrasse 12/1, 88045 Friedrichshafen
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Arctic Bioscience AS.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.